March 18, 2014 — Toronto, ON, and Vancouver, BC
Dr. Julie Ducharme, General Manager of Human Health Therapeutics at NRC, Dr. Roman Szumski, Vice-President of Life Sciences at NRC, and Dr. Ali Tehrani, President and Chief Executive Officer of Zymeworks.
The National Research Council of Canada (NRC) and Zymeworks Inc., a Canadian biotherapeutics company and a world leader in antibody therapeutics, are proud to announce a strategic collaborative agreement for a continued innovative business alliance.
This three-year multi-million dollar agreement will focus on developing ground-breaking therapies for the fight against cancer, as well as inflammatory and autoimmune diseases. Zymeworks will gain access to NRC’s unique expertise, scientific facilities, and know-how which will complement Zymeworks’ existing capabilities in the development and deployment of innovative products for local and international markets in areas of significant unmet medical need.
This partnership strengthens Zymeworks position as a strong global competitor in biotherapeutics development and is a clear demonstration of Canada’s commitment to R&D for a prosperous economy.
David Poon
Director, External R&D and Alliances
Zymeworks Inc.
604-678-1388
info@zymeworks.com
Media Relations Team
National Research Council of Canada
Telephone: 613-991-1431
Toll-free: 1-855-282-1637
Email: media@nrc-cnrc.gc.ca
Twitter: @nrc_cnrc
